The collaboration includes the initial validation and deployment of Ibex Prostate within HNL Lab Medicine’s LDT workflow.

An enlarged prostate is a big problem for men, no pun intended. According to Yale Medicine, about 50% of men between the ages of 51 and 60 have benign prostatic hyperplasia (BPH) or an enlarged ...

Modern medical research shows that drug and surgical treatments for benign prostatic hyperplasia and chronic prostatitis carry high risks, while Dr Allen's Device, developed by Fine Treatment, an ...

Vanquish uses ultrasound, transurethral and electromagnetically guided thermotherapy to ablate prostate tissue.

TORONTO, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company developing AI-powered, ...

Oxford, UK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Topical summits in Dubai, Berlin, Nanjing, Basel, Lisbon, London and other cities discussed the uniqueness of Dr Allen's Devices, a new revolutionary ...

MINNEAPOLIS, Feb. 3, 2026 /PRNewswire/ -- Francis Medical, Inc., a privately-held medical device company, announced the first commercial procedure using the Vanquish Water Vapor Ablation System at ...

MINNEAPOLIS, March 5, 2026 /PRNewswire/ -- Francis Medical, Inc., a privately held medical device company, announced today the successful completion of the first commercial (non-clinical trial) ...

The growing prevalence of chronic diseases like cancer and diabetes is driving increasing innovation in medical device technology. In 2024 alone, 30 new devices were approved by the US Food and Drug ...

TORONTO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage innovator in interventional MRI (“iMRI”) procedures, is ...